New eye drug trial offers hope for blinding disease
NCT ID NCT06672536
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 31 times
Summary
This study tests a new medicine called SCT520FF for people with neovascular age-related macular degeneration (nAMD), a condition that can cause rapid vision loss. The trial will include 82 adults aged 45 to 80 and aims to check the drug's safety and how well it works. Researchers will monitor side effects and measure changes in vision and eye health over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAMD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Eye Hospital
RECRUITINGTianjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.